Literature DB >> 25419430

Proliferation and migration of hepatoblastoma cells are mediated by IRS-4 via PI3K/Akt pathways.

Ziqiang Xia1, Ning Zhang1, Daokui Ding1.   

Abstract

Levels of IRS-4 (insulin receptor substrate-4) in hepatoblastoma cells from the patients, HepG2 and HuH-6 cell lines were measured by Western Blot analysis, and they were all found significantly higher than those of normal hepatic cells. When the HepG2 and HuH-6 cells cultivated in vitro were treated with IRS-4 and infected with recombinant adenovirus containing IRS-4 gene, the proliferation and migration of the cells were significantly improved. Meanwhile, the expressions of PI3K (phosphatidylinositol 3'-kinase), pS473 Akt (Protein Kinase B) and pThr308 Akt were positively regulated by IRS-4 overexpression. These results indicated that IRS-4 was very likely to be involved in PI3K/Akt path way, which was further confirmed by the fact that the PI3K/Akt blocker LY294002 attenuated the proliferation and migration of the hepatoblastoma cells. In conclusion, IRS-4 enhanced the proliferation and migration of the hepatoblastoma cells via PI3K/Akt pathways.

Entities:  

Keywords:  Hepatoblastoma; PI3K/Akt pathway; insulin receptor substrate-4; migration; proliferation

Year:  2014        PMID: 25419430      PMCID: PMC4238470     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  26 in total

1.  Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms.

Authors:  M Chiara Cantarini; Suzanne M de la Monte; Maoyin Pang; Ming Tong; Antonia D'Errico; Franco Trevisani; Jack R Wands
Journal:  Hepatology       Date:  2006-08       Impact factor: 17.425

Review 2.  Childhood cancers: hepatoblastoma.

Authors:  C E Herzog; R J Andrassy; F Eftekhari
Journal:  Oncologist       Date:  2000

3.  Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study.

Authors:  József Zsíros; Rudolf Maibach; Elizabeth Shafford; Laurence Brugieres; Penelope Brock; Piotr Czauderna; Derek Roebuck; Margaret Childs; Arthur Zimmermann; Veronique Laithier; Jean-Bernard Otte; Beatriz de Camargo; Gordon MacKinlay; Marcelo Scopinaro; Daniel Aronson; Jack Plaschkes; Giorgio Perilongo
Journal:  J Clin Oncol       Date:  2010-04-20       Impact factor: 44.544

Review 4.  [Intracellular signals involved in glucose control].

Authors:  M Cruz; E Velasco; J Kumate
Journal:  Gac Med Mex       Date:  2001 Mar-Apr       Impact factor: 0.302

5.  Role of IRS-4 in PI3-K activation by insulin in HepG2 cells, modulation by Angiotensin II.

Authors:  Rodrigo Sebastián Villarreal; Myriam Liliana Forneris; Romina María Uranga; Gabriela Alejandra Salvador; Gladys María Ciuffo
Journal:  Regul Pept       Date:  2010-01-14

6.  Insulin receptor substrate 4 couples the leptin receptor to multiple signaling pathways.

Authors:  Joris Wauman; Anne-Sophie De Smet; Dominiek Catteeuw; Denise Belsham; Jan Tavernier
Journal:  Mol Endocrinol       Date:  2007-12-28

Review 7.  PTEN and the PI3-kinase pathway in cancer.

Authors:  Nader Chalhoub; Suzanne J Baker
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

8.  Novel phosphotyrosine targets of FGFR2IIIb signaling.

Authors:  Yongde Luo; Chaofeng Yang; Chengliu Jin; Rui Xie; Fen Wang; Wallace L McKeehan
Journal:  Cell Signal       Date:  2009-05-03       Impact factor: 4.315

9.  Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells.

Authors:  Neeraj K Saxena; Dipali Sharma; Xiaokun Ding; Songbai Lin; Fabio Marra; Didier Merlin; Frank A Anania
Journal:  Cancer Res       Date:  2007-03-15       Impact factor: 12.701

10.  Insulin receptor substrate-1 associates with small nucleolar RNA which contributes to ribosome biogenesis.

Authors:  Atsufumi Ozoe; Meri Sone; Toshiaki Fukushima; Naoyuki Kataoka; Kazuhiro Chida; Tomoichiro Asano; Fumihiko Hakuno; Shin-Ichiro Takahashi
Journal:  Front Endocrinol (Lausanne)       Date:  2014-03-04       Impact factor: 5.555

View more
  4 in total

1.  Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking.

Authors:  Joachim Weischenfeldt; Taronish Dubash; Alexandros P Drainas; Balca R Mardin; Yuanyuan Chen; Adrian M Stütz; Sebastian M Waszak; Graziella Bosco; Ann Rita Halvorsen; Benjamin Raeder; Theocharis Efthymiopoulos; Serap Erkek; Christine Siegl; Hermann Brenner; Odd Terje Brustugun; Sebastian M Dieter; Paul A Northcott; Iver Petersen; Stefan M Pfister; Martin Schneider; Steinar K Solberg; Erik Thunissen; Wilko Weichert; Thomas Zichner; Roman Thomas; Martin Peifer; Aslaug Helland; Claudia R Ball; Martin Jechlinger; Rocio Sotillo; Hanno Glimm; Jan O Korbel
Journal:  Nat Genet       Date:  2016-11-21       Impact factor: 38.330

2.  Low dosage of arsenic trioxide inhibits vasculogenic mimicry in hepatoblastoma without cell apoptosis.

Authors:  Feng Zhang; Chun-Mei Zhang; Shu Li; Kun-Kun Wang; Bin-Bin Guo; Yao Fu; Lu-Yang Liu; Yu Zhang; Hai-Yu Jiang; Chang-Jun Wu
Journal:  Mol Med Rep       Date:  2017-11-14       Impact factor: 2.952

3.  Chronic venous disease patients show increased IRS-4 expression in the great saphenous vein wall.

Authors:  Miguel A Ortega; Oscar Fraile-Martínez; Cielo García-Montero; Fernando Ruiz-Grande; Silve Barrena; Hector Montoya; Leonel Pekarek; Sofia Zoullas; Miguel A Alvarez-Mon; Felipe Sainz; Angel Asúnsolo; Julio Acero; Melchor Álvarez-Mon; Julia Buján; Natalio García-Honduvilla; Luis G Guijarro
Journal:  J Int Med Res       Date:  2021-09       Impact factor: 1.671

4.  miR-30a-3p inhibits the proliferation of liver cancer cells by targeting DNMT3a through the PI3K/AKT signaling pathway.

Authors:  Qiong Chen; Yuan Gao; Qin Yu; Feng Tang; Pei-Wei Zhao; Su-Kun Luo; Ju-Sheng Lin; Hong Mei
Journal:  Oncol Lett       Date:  2019-12-03       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.